Ginkgo Bioworks Holdings, Inc. ownership disclosure: Viking Global Investors and affiliated entities report shared beneficial ownership of 3,577,128 shares of Class A Common Stock. The filing amends prior reports to remove David C. Ott as a reporting person effective March 31, 2026.
The filing states those 3,577,128 shares represent 7.1% of Class A Common Stock based on 50,254,065 shares outstanding as of March 31, 2026. The stake includes 2,900,025 directly held shares and 677,103 shares subject to forfeiture if price targets are not met.
Ginkgo Bioworks Holdings, Inc. ownership disclosure: Viking Global Investors and affiliated entities report shared beneficial ownership of 3,577,128 shares of Class A Common Stock. The filing amends prior reports to remove David C. Ott as a reporting person effective March 31, 2026.
The filing states those 3,577,128 shares represent 7.1% of Class A Common Stock based on 50,254,065 shares outstanding as of March 31, 2026. The stake includes 2,900,025 directly held shares and 677,103 shares subject to forfeiture if price targets are not met.
Austin Che submitted a Form 144 reporting proposed sales of Class A shares. The notice lists 2,200 Class A shares tied to a Restricted Stock Vesting dated 10/20/2022. The filing also records securities sold during the past three months: 2,200 shares on 03/11/2026, 40,893 shares on 04/13/2026 (showing $262,291.79), and 2,200 shares on 04/15/2026. The broker identified is Fidelity Brokerage Services LLC.
Austin Che submitted a Form 144 reporting proposed sales of Class A shares. The notice lists 2,200 Class A shares tied to a Restricted Stock Vesting dated 10/20/2022. The filing also records securities sold during the past three months: 2,200 shares on 03/11/2026, 40,893 shares on 04/13/2026 (showing $262,291.79), and 2,200 shares on 04/15/2026. The broker identified is Fidelity Brokerage Services LLC.
Ginkgo Bioworks Holdings, Inc. reported another quarterly loss while executing a major portfolio shift in early 2026. For the three months ended March 31, 2026, revenue from continuing operations was $19.5 million, with a net loss from continuing operations of $76.1 million and total net loss of $82.6 million.
The company completed a strategic divestiture of its Biosecurity business: in April 2026 it transferred substantially all Biosecurity operations to Perimeter Systems in exchange for an equity stake representing about 20% of the purchaser on a fully diluted basis. Biosecurity results are now reported as discontinued operations, contributing a further $6.5 million loss in the quarter.
As of March 31, 2026, Ginkgo held $143.9 million in cash and cash equivalents and $229.6 million in marketable securities, with total assets of $1.03 billion and stockholders’ equity of $443.2 million. Operating activities used $46.7 million of cash in the quarter, and a previously unrestricted $47.0 million of cash became restricted in April 2026 to secure a surety bond tied to an automation equipment contract.
Ginkgo Bioworks Holdings, Inc. reported another quarterly loss while executing a major portfolio shift in early 2026. For the three months ended March 31, 2026, revenue from continuing operations was $19.5 million, with a net loss from continuing operations of $76.1 million and total net loss of $82.6 million.
The company completed a strategic divestiture of its Biosecurity business: in April 2026 it transferred substantially all Biosecurity operations to Perimeter Systems in exchange for an equity stake representing about 20% of the purchaser on a fully diluted basis. Biosecurity results are now reported as discontinued operations, contributing a further $6.5 million loss in the quarter.
As of March 31, 2026, Ginkgo held $143.9 million in cash and cash equivalents and $229.6 million in marketable securities, with total assets of $1.03 billion and stockholders’ equity of $443.2 million. Operating activities used $46.7 million of cash in the quarter, and a previously unrestricted $47.0 million of cash became restricted in April 2026 to secure a surety bond tied to an automation equipment contract.
Ginkgo Bioworks Holdings, Inc. reported first quarter 2026 results and highlighted its post-divestiture focus on autonomous labs. Revenue was $19.5 million, down 49% from the prior year quarter, largely due to program rationalization and the absence of prior non-cash deferred revenue releases.
The company posted a GAAP net loss from continuing operations of $76.1 million, modestly improved from $83.3 million a year earlier, and an Adjusted EBITDA loss of $42.3 million compared with $44.2 million. Cash, cash equivalents and marketable securities totaled $373 million as of March 31, 2026.
Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026, which is now reported as discontinued operations. Management emphasized scaling its Nebula autonomous lab, growth in its Cloud Lab, Datapoints and Solutions offerings, and reaffirmed expected full-year 2026 total cash burn of $(150)–$(125) million.
Ginkgo Bioworks Holdings, Inc. reported first quarter 2026 results and highlighted its post-divestiture focus on autonomous labs. Revenue was $19.5 million, down 49% from the prior year quarter, largely due to program rationalization and the absence of prior non-cash deferred revenue releases.
The company posted a GAAP net loss from continuing operations of $76.1 million, modestly improved from $83.3 million a year earlier, and an Adjusted EBITDA loss of $42.3 million compared with $44.2 million. Cash, cash equivalents and marketable securities totaled $373 million as of March 31, 2026.
Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026, which is now reported as discontinued operations. Management emphasized scaling its Nebula autonomous lab, growth in its Cloud Lab, Datapoints and Solutions offerings, and reaffirmed expected full-year 2026 total cash burn of $(150)–$(125) million.
Ginkgo Bioworks Holdings, Inc. is asking shareholders to vote at its virtual 2026 annual meeting on June 11, 2026 at 8:00 a.m. Eastern Time. Shareholders will elect six directors, ratify Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and cast an advisory vote on executive compensation, with the Board recommending “FOR” each item.
Holders of Class A common stock have one vote per share and holders of Class B common stock have ten votes per share, with 53,172,097 Class A shares and 8,963,350 Class B shares outstanding as of April 15, 2026. The proxy describes Ginkgo’s dual‑class governance, board committee structure, director pay (cash retainers plus stock options), and a pay program that emphasizes equity, including performance‑based restricted stock units for executives.
The filing also notes Deloitte audit fees of $4,042,215 for 2025 and summarizes the 2024 transition from EY to Deloitte, including previously reported material weaknesses in internal control over financial reporting. Shareholders may vote online, by phone, by mail, or during the virtual meeting.
Ginkgo Bioworks Holdings, Inc. is asking shareholders to vote at its virtual 2026 annual meeting on June 11, 2026 at 8:00 a.m. Eastern Time. Shareholders will elect six directors, ratify Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and cast an advisory vote on executive compensation, with the Board recommending “FOR” each item.
Holders of Class A common stock have one vote per share and holders of Class B common stock have ten votes per share, with 53,172,097 Class A shares and 8,963,350 Class B shares outstanding as of April 15, 2026. The proxy describes Ginkgo’s dual‑class governance, board committee structure, director pay (cash retainers plus stock options), and a pay program that emphasizes equity, including performance‑based restricted stock units for executives.
The filing also notes Deloitte audit fees of $4,042,215 for 2025 and summarizes the 2024 transition from EY to Deloitte, including previously reported material weaknesses in internal control over financial reporting. Shareholders may vote online, by phone, by mail, or during the virtual meeting.
Ginkgo Bioworks Holdings, Inc. officer Steven P. Coen reported routine equity compensation activity involving restricted stock units. On April 16, 2026, he exercised RSUs to acquire a total of 743 shares of Class A Common Stock at a conversion price of $0.00 per share, reflecting vesting of previously granted awards.
On April 17, 2026, Coen sold 324 shares of Class A Common Stock at an average price of $7.952 per share. According to the disclosure, these shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock and RSUs and are not considered discretionary trades. After these transactions, he directly holds 50,268 shares of Class A Common Stock.
Ginkgo Bioworks Holdings, Inc. officer Steven P. Coen reported routine equity compensation activity involving restricted stock units. On April 16, 2026, he exercised RSUs to acquire a total of 743 shares of Class A Common Stock at a conversion price of $0.00 per share, reflecting vesting of previously granted awards.
On April 17, 2026, Coen sold 324 shares of Class A Common Stock at an average price of $7.952 per share. According to the disclosure, these shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock and RSUs and are not considered discretionary trades. After these transactions, he directly holds 50,268 shares of Class A Common Stock.
DNA filed a Form 144 reporting proposed sales of Class A shares. The notice lists a proposed sale of 324 Class A shares tied to restricted stock vesting dated 04/16/2026. It also discloses recent reported sales by Steve Coen: 972 shares on 01/20/2026, 708 shares on 03/16/2026, and 33,171 shares on 04/13/2026, each with the corresponding proceeds shown in the filing.
DNA filed a Form 144 reporting proposed sales of Class A shares. The notice lists a proposed sale of 324 Class A shares tied to restricted stock vesting dated 04/16/2026. It also discloses recent reported sales by Steve Coen: 972 shares on 01/20/2026, 708 shares on 03/16/2026, and 33,171 shares on 04/13/2026, each with the corresponding proceeds shown in the filing.
DNA submitted a Rule 144 notice reporting proposed resales of Class A common stock. The notice lists sale entries by Austin Che on 02/04/2026 (2,200 shares), 03/11/2026 (2,200 shares) and 04/13/2026 (40,893 shares) with proceeds of $262,291.79 shown for the 04/13/2026 entry. The filing also records a restricted stock vesting date of 10/20/2022 and names Fidelity Brokerage Services LLC as a broker on the notice.
DNA submitted a Rule 144 notice reporting proposed resales of Class A common stock. The notice lists sale entries by Austin Che on 02/04/2026 (2,200 shares), 03/11/2026 (2,200 shares) and 04/13/2026 (40,893 shares) with proceeds of $262,291.79 shown for the 04/13/2026 entry. The filing also records a restricted stock vesting date of 10/20/2022 and names Fidelity Brokerage Services LLC as a broker on the notice.
Ginkgo Bioworks Holdings, Inc. executive Steven P. Coen reported PSU vesting and related share activity. On April 10, 2026, he acquired a total of 73,921 shares of Class A Common Stock through the vesting and conversion of performance-based restricted stock units.
On April 13, 2026, he sold 33,171 shares at $6.414 per share solely to cover tax withholding obligations under a mandatory “sell to cover” mechanism, which the company’s equity plans permit and which is described as non-discretionary. After these transactions, he held 49,849 shares directly.
The PSUs were tied to cash flow reduction performance targets for the finance team and company-wide. One 45,755-PSU grant vested at 62% of its target, and a 67,991-PSU grant vested at 67%, as certified by the Compensation Committee.
Ginkgo Bioworks Holdings, Inc. executive Steven P. Coen reported PSU vesting and related share activity. On April 10, 2026, he acquired a total of 73,921 shares of Class A Common Stock through the vesting and conversion of performance-based restricted stock units.
On April 13, 2026, he sold 33,171 shares at $6.414 per share solely to cover tax withholding obligations under a mandatory “sell to cover” mechanism, which the company’s equity plans permit and which is described as non-discretionary. After these transactions, he held 49,849 shares directly.
The PSUs were tied to cash flow reduction performance targets for the finance team and company-wide. One 45,755-PSU grant vested at 62% of its target, and a 67,991-PSU grant vested at 67%, as certified by the Compensation Committee.
Ginkgo Bioworks Holdings, Inc. major holder Canton Barry reported his spouse’s performance-based equity vesting and related tax sale. On April 9, 2026, 251,786 performance-based restricted stock units converted into an equal number of Class A shares at a $0.00 exercise price.
These PSUs came from a 375,800-unit grant tied to a company-wide cash flow reduction target for January 1, 2025 through December 31, 2025, with actual performance certified at 67% of target. On April 10, 2026, Barry’s spouse sold 124,727 Class A shares at $6.434 per share solely to cover tax withholding obligations under the issuer’s equity incentive plans, which the filing states were non-discretionary “sell to cover” transactions. After these transactions, 436,422 Class A shares were held indirectly through his spouse.
Ginkgo Bioworks Holdings, Inc. major holder Canton Barry reported his spouse’s performance-based equity vesting and related tax sale. On April 9, 2026, 251,786 performance-based restricted stock units converted into an equal number of Class A shares at a $0.00 exercise price.
These PSUs came from a 375,800-unit grant tied to a company-wide cash flow reduction target for January 1, 2025 through December 31, 2025, with actual performance certified at 67% of target. On April 10, 2026, Barry’s spouse sold 124,727 Class A shares at $6.434 per share solely to cover tax withholding obligations under the issuer’s equity incentive plans, which the filing states were non-discretionary “sell to cover” transactions. After these transactions, 436,422 Class A shares were held indirectly through his spouse.